Barclays Maintains an 'Overweight' on ISIS Pharmaceuticals (ISIS); 4Q10 Update - Mipomersen Filings on Track
Tweet Send to a Friend
Barclays maintains an 'Overweight' on ISIS Pharmaceuticals (NASDAQ: ISIS), PT $17.
Barclays analyst says, "While most of the focus ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "While most of the focus ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
